GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseBio Pharmaceuticals Inc (OTCPK:PHASQ) » Definitions » EPS without NRI

PHASQ (PhaseBio Pharmaceuticals) EPS without NRI : $-2.17 (TTM As of Jun. 2022)


View and export this data going back to 2018. Start your Free Trial

What is PhaseBio Pharmaceuticals EPS without NRI?

PhaseBio Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Jun. 2022 was $-0.52. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2022 was $-2.17.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for PhaseBio Pharmaceuticals's EPS without NRI or its related term are showing as below:

PHASQ's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 12.35
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

PhaseBio Pharmaceuticals's EPS (Diluted) for the three months ended in Jun. 2022 was $-0.34. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-2.13.

PhaseBio Pharmaceuticals's EPS (Basic) for the three months ended in Jun. 2022 was $-0.34. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2022 was $-2.13.


PhaseBio Pharmaceuticals EPS without NRI Historical Data

The historical data trend for PhaseBio Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhaseBio Pharmaceuticals EPS without NRI Chart

PhaseBio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EPS without NRI
Get a 7-Day Free Trial -15.07 -4.37 -1.43 -2.96 -2.63

PhaseBio Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Apr24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.60 -0.68 -0.38 -0.52 -

Competitive Comparison of PhaseBio Pharmaceuticals's EPS without NRI

For the Biotechnology subindustry, PhaseBio Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhaseBio Pharmaceuticals's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhaseBio Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where PhaseBio Pharmaceuticals's PE Ratio without NRI falls into.


;
;

PhaseBio Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PhaseBio Pharmaceuticals  (OTCPK:PHASQ) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


PhaseBio Pharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of PhaseBio Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


PhaseBio Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
1 Great Valley Parkway, Suite 30, Malvern, PA, USA, 19355
PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension. The company is also developing its preclinical product candidate, PB6440, for treatment-resistant hypertension.
Executives
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Glen Burkhardt officer: VP, Human Resources C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY.,SUITE 30, MALVERN PA 19355
Jonathan Birchall officer: Chief Commercial Officer C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PARKWAY, SUITE 30, MALVERN PA 19355
William D. Humphries director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Clay Thorp director C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Edmund Harrigan director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Van Den Broek Richard director 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Peter Justin Klein director 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
David James Ballance officer: VP, Research and Sci. Affairs C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Michael York officer: VP, Corporate Development C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
John Sang Lee officer: Chief Medical Officer C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Susan Elizabeth Arnold officer: VP, Preclinical and Chem C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY DRIVE, SUITE 30, MALVERN PA 19355
Kristopher Hanson officer: VP, Head of Legal C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355

PhaseBio Pharmaceuticals Headlines

From GuruFocus

PhaseBio Appoints William D. Humphries to Board of Directors

By Business Wire Business Wire 09-15-2021